Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175
American Journal of Cancer Research · 2026 · 16 (10) · 4674-4675
DOI: 10.62347/szdy9971 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Yongpeng Li und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, Y., Li, L., Fu, H., Yao, Q., Wang, L., & Lou, L. (2026). Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175. American Journal of Cancer Research, 16(10), 4674-4675. https://doi.org/10.62347/szdy9971
Vancouver
Li Y, Li L, Fu H, Yao Q, Wang L, Lou L. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175. American Journal of Cancer Research. 2026;16(10):4674-4675. doi:10.62347/szdy9971
BibTeX
@article{Li2026,
author = {Li, Yongpeng and Li, Lin and Fu, Haoyu and Yao, Qing and Wang, Lei and Lou, Liguang},
title = {Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {10},
pages = {4674--4675},
doi = {10.62347/szdy9971}
}
EUVIMED